FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963673927> ?p ?o ?g. }

• W1963673927 endingPage "156" @default.
• W1963673927 startingPage "141" @default.
• W1963673927 abstract "Increased resistance to portal blood flow is the primary factor in the pathophysiology of portal hypertension, and is mainly determined by the morphological changes occurring in chronic liver diseases. This is aggravated by a dynamic component, due to the active-reversible- contraction of different elements of the porto-hepatic bed. A decreased synthesis of NO in the intrahepatic circulation is the main determinant of this dynamic component. This provides a rationale for the use of vasodilators to reduce intrahepatic resistance and portal pressure. Another factor contributing to aggravate the portal hypertension is a significant increase in portal blood flow, caused by arteriolar splanchnic vasodilation and hyperkinetic circulation. Splanchnic arteriolar vasodilation is a multifactorial phenomenon, which may involve local (endothelial) mechanisms as well as neurogenic and humoral pathways. Most pharmacological treatments have been aimed at correcting the increased portal blood inflow by the use of splanchnic vasoconstrictors, such as beta-blockers, vasopressin derivatives and somatostatin. Several studies have demonstrated that changes in the hepatic venous pressure gradient (HVPG) during maintenance therapy are useful to identify those patients who are going to have a variceal bleeding or rebleeding. The wide individual variation in the HVPG response to pharmacological treatment makes it desirable to schedule follow-up measurements of HVPG during pharmacological therapy. A priority for research in the forthcoming years is to develop accurate non-invasive methods to assess prognosis, which can be used to substitute or as surrogate indicators of the HVPG response. In the clinical management of portal hypertension, beta-blockers are at present the only accepted treatment for the prevention of variceal bleeding. Whether the association of isosorbide-5-mononitrate will improve the high efficacy of beta-blockers is questionable. The efficacy of more aggressive techniques, such as endoscopic band ligation, should be further tested against beta-blockers in patients with a high risk of bleeding. In the treatment of acute variceal bleeding, administration of somatostatin or terlipressin is an established therapy. It may be used alone or, preferably, as an initial treatment before sclerotherapy or endoscopic band ligation. No more than two sessions of endoscopic treatment should be used to control the bleeding. If the bleeding is not easily controlled, other alternatives such as transjugular intrahepatic portosystemic shunts (TIPS) or derivative surgery should be considered, the former being the best in patients with poor liver function. Recent studies suggest that early measurement of HVPG during variceal bleeding may be used as a guide for therapeutic decisions in the treatment of patients with acute variceal bleeding. Those patients with a high HVPG have a high risk of poor evolution, and may be candidates for more intensive and aggressive therapy, such as surgery or TIPS. Those with lower HVPG have a very high probability of an uneventful evolution, and may thus be managed more conservatively using medical and endoscopic treatments. Pharmacological agents (propranolol or nadolol), endoscopic treatment (preferably banding ligation) or surgery can be used to prevent rebleeding. A pending task for the new millennium is to assess whether the early treatment of asymptomatic, compensated cirrhotic patients with portal pressure reducing agents can prevent the development of esophageal varices and of other complications of portal hypertension." @default.
• W1963673927 created "2016-06-24" @default.
• W1963673927 creator A5001524643 @default.
• W1963673927 creator A5012387403 @default.
• W1963673927 date "2000-01-01" @default.
• W1963673927 modified "2023-10-17" @default.
• W1963673927 title "Complications of cirrhosis. I. Portal hypertension" @default.
• W1963673927 cites W101090077 @default.
• W1963673927 cites W122518412 @default.
• W1963673927 cites W1267147680 @default.
• W1963673927 cites W1490907837 @default.
• W1963673927 cites W1502333213 @default.
• W1963673927 cites W1537279861 @default.
• W1963673927 cites W1575024810 @default.
• W1963673927 cites W1615440957 @default.
• W1963673927 cites W1632973114 @default.
• W1963673927 cites W1654091726 @default.
• W1963673927 cites W1666404037 @default.
• W1963673927 cites W1798628354 @default.
• W1963673927 cites W1825548390 @default.
• W1963673927 cites W1829799337 @default.
• W1963673927 cites W1851882079 @default.
• W1963673927 cites W1861192650 @default.
• W1963673927 cites W1901319567 @default.
• W1963673927 cites W1967396537 @default.
• W1963673927 cites W1973164007 @default.
• W1963673927 cites W1973314937 @default.
• W1963673927 cites W1973376522 @default.
• W1963673927 cites W1977983569 @default.
• W1963673927 cites W1978827285 @default.
• W1963673927 cites W1980734258 @default.
• W1963673927 cites W1987683819 @default.
• W1963673927 cites W1989304720 @default.
• W1963673927 cites W1991110995 @default.
• W1963673927 cites W1991236355 @default.
• W1963673927 cites W1991615383 @default.
• W1963673927 cites W1994397083 @default.
• W1963673927 cites W1994526215 @default.
• W1963673927 cites W2003161857 @default.
• W1963673927 cites W2003458286 @default.
• W1963673927 cites W2005978449 @default.
• W1963673927 cites W2006353616 @default.
• W1963673927 cites W2007677328 @default.
• W1963673927 cites W2009149270 @default.
• W1963673927 cites W2010812148 @default.
• W1963673927 cites W2010918676 @default.
• W1963673927 cites W2011457139 @default.
• W1963673927 cites W2017371355 @default.
• W1963673927 cites W2018042542 @default.
• W1963673927 cites W2018946904 @default.
• W1963673927 cites W2023145731 @default.
• W1963673927 cites W2024253791 @default.
• W1963673927 cites W2024642291 @default.
• W1963673927 cites W2025606754 @default.
• W1963673927 cites W2026247579 @default.
• W1963673927 cites W2027387864 @default.
• W1963673927 cites W2027392197 @default.
• W1963673927 cites W2028020420 @default.
• W1963673927 cites W2029427854 @default.
• W1963673927 cites W2032541468 @default.
• W1963673927 cites W2039692235 @default.
• W1963673927 cites W2039923830 @default.
• W1963673927 cites W2039945220 @default.
• W1963673927 cites W2041553454 @default.
• W1963673927 cites W2041714207 @default.
• W1963673927 cites W2044276584 @default.
• W1963673927 cites W2044457468 @default.
• W1963673927 cites W2046073530 @default.
• W1963673927 cites W2047024864 @default.
• W1963673927 cites W2047287628 @default.
• W1963673927 cites W2047398086 @default.
• W1963673927 cites W2047865739 @default.
• W1963673927 cites W2049349698 @default.
• W1963673927 cites W2051080184 @default.
• W1963673927 cites W2052113409 @default.
• W1963673927 cites W2056695599 @default.
• W1963673927 cites W2056980354 @default.
• W1963673927 cites W2058138382 @default.
• W1963673927 cites W2062811388 @default.
• W1963673927 cites W2066644775 @default.
• W1963673927 cites W2067864626 @default.
• W1963673927 cites W2067871419 @default.
• W1963673927 cites W2069465728 @default.
• W1963673927 cites W2071142226 @default.
• W1963673927 cites W2072743531 @default.
• W1963673927 cites W2074863268 @default.
• W1963673927 cites W2079466574 @default.
• W1963673927 cites W2089482666 @default.
• W1963673927 cites W2089602353 @default.
• W1963673927 cites W2093463196 @default.
• W1963673927 cites W2094144954 @default.
• W1963673927 cites W2098429553 @default.
• W1963673927 cites W2103588891 @default.
• W1963673927 cites W2110305967 @default.
• W1963673927 cites W2111507306 @default.
• W1963673927 cites W2111850114 @default.
• W1963673927 cites W2119658569 @default.
• W1963673927 cites W2119790378 @default.

• next